Advertisement

Related Videos

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Advertisement

Advertisement




Feb
07
Today In Oncology
A Paradigm Shift In Treating Adult AML?
Lymph Node Examination Should be Expanded to Accurately Assess Metastasis in NSCLC, Research Says
VTE During Perioperative Therapy in Resectable and Borderline Resectable Pancreatic Cancer
Agent Orange Exposure Linked With Risk for Acral Melanoma in Veterans
FDA Provides Safety Labeling Update for Capecitabine and Fluorouracil on Risks Associated With DPD Deficiency
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo